Butterfly Network, Inc. ("Butterfly") , a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced that ...

The Galien Foundation was established to foster and reward outstanding achievements in improving the global human condition ...

Belzutifan has a “generally manageable” safety profile in patients with RCC, with a relatively low rate of treatment discontinuation.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

Let's explore two magnificent stocks near a 52-week low to buy now. Pharmaceutical giant Merck(NYSE: MRK) is recognized for ...